Commissioning Policies – now the responsibility of NHS England
Since April 2013, NHS England has responsibility for directly commissioning all prescribed specialised services. 'Prescribed' specialised services are those 'tested'’ against the four factors in the Health and Social Care Act 2012 as suitable for commissioning by NHS England. 

This means that some commissioning policies which were agreed by the previous commissioning organisations are no longer valid as the commissioning of these areas is now the responsibility of NHS England.

Listed below are the former policies which this has affected:
  • Abiraterone for the treatment of hormone refractory metastatic prostate cancer
  • Alemtuzumab in chronic lymphocytic leukaemia who have the 17p gene deletion 
  • Alemtuzumab for the treatment of T-cell prolymphocytic leukaemia following progression on at least one prior treatment 
  • Bevacizumab as first line treatment of K RAS mutant metastatic colorectal cancer (mCRC) patients with liver only metastases with potential for resection after treatment 
  • Blood and marrow transplantation
  • Bone Anchored Hearing Aids
  • Cabazitaxel for the treatment of hormone refractory metastatic prostate cancer
  • Co-careldopa intestinal gel (Duodopa®) for Parkinson’s disease
  • Cochlear Implants
  • Cyberknife Stereotactic Radiosurgery for Spinal Schwannoma
  • Cystic fibrosis transition from paediatric to adult care
  • Dasatinib and nilotinib in the management of chronic myeloid leukaemia
  • Deep brain stimulation for Parkinson’s disease
  • Deferasirox for transfusion dependent iron overload 
  • Dental Implants
  • Docetaxel as part of an induction regimen for head and neck cancer
  • Epilepsy surgery
  • Erlotinib as first line treatment for patients with advanced EGFR mutation positive non small cell lung cancer (NSCLC)
  • Fampridine for the improvement of walking ability in patients with multiple sclerosis
  • Febrile neutropenia prophylaxis with granulocyte colony stimulating factors (GCSF’s) 
  • Firdapse for the treatment of Lambert-Eaton myasthenic syndrome and Congenital Myasthenia Syndromes
  • Gender Dysphoria Treatment
  • Haemophilia transition from paediatric to adult care
  • Icatibant in the treatment of acute attacks of hereditary angioedema
  • Intrathecal Baclofen for Severe Spasticity in Adults
  • Lapatinib for HER2-positive metastic breast cancer that has progressed outside the central nervous system on treatment with trastuzumab
  • Orthodontics for adults
  • Penile prosthesis surgery for end stage erectile dysfunction
  • Planned Treatment Abroad - Further details can now be found here
  • Rituximab for severe ANCA-associated vasculitis
  • Sacral nerve and faecal continence 
  • Stereotactic radiosurgery and radiotherapy - cranial
  • Temoporfin for use with PDT for head and neck cancers
  • Transoral robotic surgery for cancers of the tonsil, supraglottic larynx and base of tongue
  • Vagal nerve stimulation
  • Ziconotide for severe, chronic pain in patients requring intrathecal analgesia 

The NHS England website can be accessed via the link below:  
NHS England
Rate this Page.
Great
Okay
Bad